Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Lunai Bioworks Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.04
Cost of revenue
0.01
Gross profit
0.04
Research and development
0.8
0.06
0.62
2.5
4.69
15.7
8.37
4.17
2.71
0.54
General and administrative
1.23
0.93
3.9
8.42
7.12
7.56
14.3
15.3
24.6
17.9
Operating expenses
2.16
2.4
5.33
11
11.9
23.4
116
38.6
81.6
189
Operating income
-2.12
-2.4
-5.33
-11
-11.9
-23.4
-116
-38.6
-81.6
-189
Interest expense
0
0.14
0
0.1
0.38
0.37
0.58
1.01
0.73
Interest income
0.05
0.07
0.05
0.01
0.12
Other non-operating income
-0.08
0.19
-1.09
-7.03
0.51
-3.45
2.65
-1.13
-6.79
11
Pre-tax income
-2.2
-2.21
-6.42
-18
-11.4
-26.8
-113
-39.7
Income tax
-0.46
-0.06
-0.11
-0.13
0
0
0
Net income
-1.74
-2.14
-6.31
-18
-11.4
-26.7
-113
-39.7
-88.4
-178
EBITDA
-2.09
-2.39
-5.31
-10.9
-11.8
-23.3
-116
-38.4
-81.5
-189
EPS, basic
-0.12
-0.12
-0.29
-0.48
-0.25
-0.57
-2.16
-0.71
-0.91
-1.08
EPS, diluted
-0.12
-0.12
-0.29
-0.48
-0.25
-0.57
-2.16
-0.71
-0.91
-1.08
Shares, basic (weighted)
13.8
17.8
21.9
37.6
46.3
47.2
52.5
56.3
97.5
165
Shares, diluted (weighted)
13.8
17.8
21.9
37.6
46.3
47.2
52.5
56.3
97.5
165
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.02
3.94
15.6
12.3
8.7
20.7
9.17
1.87
0.22
0.09
Other current assets
0.01
0.03
0.04
0.19
0.24
0.23
0.39
0.67
Total current assets
0.73
4.2
15.8
12.5
8.94
20.9
9.57
2.57
2
1.05
Property, plant and equipment
0.03
0.69
0.78
0.72
0.59
0.51
0.48
0.37
Lease right-of-use assets
1.7
1.44
1.16
0.91
1.27
0.69
Goodwill
11.6
11.6
11.6
11.6
11.6
11.6
159
5.96
Intangible assets
0.14
0.12
148
0.09
0.08
0.07
0.04
0.04
0.03
0.17
Other non-current assets
168
168
74.5
55.2
161
6.82
Total assets
0.87
4.52
183
180
178
190
84.6
58.3
163
8.23
Accounts payable
1.09
0.43
0.57
0.54
0.59
0.32
1.4
5.3
9.45
12.6
Accrued liabilities
0.22
0.23
0.07
0.34
0.47
1.18
1.03
0.72
5.31
5.84
Total current liabilities
1.51
2.99
0.87
1.11
1.33
1.89
6.45
11
30.3
29.2
Long-term debt
4.58
4.58
4.58
Lease liabilities
1.53
1.24
0.99
0.78
0.84
0.42
Other non-current liabilities
0.17
0.18
0.23
0.27
Total liabilities
1.51
2.99
23.8
6.78
11.8
14.9
12
11.8
31.2
29.6
Total debt
0.1
Paid-in capital
25.1
29.6
193
226
230
266
277
291
465
478
Retained earnings
-26.3
-28.4
-34.8
-52.8
-64.2
-90.9
-204
-244
-332
-510
Other comprehensive income
0.56
0.35
0.21
0.1
-0.04
-0.01
-0.03
-0.03
-0.17
10.8
Shareholders' equity
-0.64
1.53
159
173
166
175
72.6
46.5
132
-21.3
Total equity
-0.64
1.53
159
173
166
175
72.6
46.5
132
-21.3
Total liabilities and equity
0.87
4.52
183
180
178
190
84.6
58.3
163
8.23
Shares outstanding
13.8
18
36.2
45.3
46.5
52.2
53
63.7
158
17.7
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-1.74
-2.53
-9.15
-18
-11.4
-26.7
-113
-39.7
-88.4
-178
Depreciation and amortization
0.03
0.01
0.02
0.07
0.11
0.12
0.12
0.11
0.12
0.13
Stock-based compensation
0
0.63
0.06
2.12
0.88
1.3
5.24
3.54
4.67
3.31
Deferred income tax
0
0
0
Change in receivables
-0.26
Change in payables
0.57
-0.65
0.12
-0.03
0.06
-0.27
1.08
3.89
4.06
3.11
Cash from operations
-1.47
-1.18
-4.34
-8.51
-10.5
-20.6
-15.7
-11.8
-11
-7.87
Capital expenditures
-0.03
-0.72
-0.18
-0.05
-0.01
-0.03
-0.07
Acquisitions
-0.29
Cash from investing
1.05
-0.2
-0.58
-0.72
-0.18
-0.05
-0.01
-0.03
-1.26
-0.5
Debt issued
0
3.77
0
Stock issued
3.51
16.7
0.07
0
1.16
Cash from financing
5.51
16.7
6.02
7.2
32.6
4.25
4.52
10.5
8.38
Exchange rate effect
0.02
-0.21
-0.14
-0.11
-0.14
0.03
-0.01
-0.01
0.06
-0.14
Net change in cash
-0.4
3.92
11.7
-3.32
-3.59
12
-11.5
-7.3
-1.65
-0.13
Free cash flow
-4.37
-9.22
-10.6
-20.7
-15.7
-11.8
-11
Interest paid
0.02
0.14
0
0.09
0.08
0.35
0.02
0.02
Income taxes paid
0.06
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to March 31, 2026; growth uses fiscal years. Valuation uses the share price of $1.93 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-1,301.0%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-116.2%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-95.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-54.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-45.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
69.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
46.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
28.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.19x
Current assets / current liabilities.
Quick ratio
0.16x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.16x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.21
Cash from operations / diluted weighted shares.
Book value per share
-$0.27
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-1,466.0%
Net income / market cap (the inverse of P/E).
Was Lunai Bioworks Inc. profitable in fiscal 2025?
No. It reported a net loss of $178.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.